Letter to the Editor: Commentary on "Bevacizumab Alone Versus Bevacizumab Plus Irinotecan in Patients With Recurrent Glioblastoma"
J Korean Med Sci
.
2024 Oct 28;39(41):e323.
doi: 10.3346/jkms.2024.39.e323.
Author
Paolo Tini
1
Affiliation
1
Department of Medical Sciences, Surgery and Neuroscience, Università di Siena, Siena, Italy.
[email protected]
.
PMID:
39468950
PMCID:
PMC11519056
DOI:
10.3346/jkms.2024.39.e323
No abstract available
Publication types
Letter
Comment